Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 36,211,324	$ 19,174,061
Marketable securities	3,011,693	7,080,053
Accounts receivable, net of allowance for doubtful accounts of $382,721 and $385,362 at June 30, 2015 and December 31, 2014, respectively	1,297,538	3,111,274
Deferred costs	2,973,487	2,566,989
Prepaid expenses and other current assets	3,980,547	4,349,167
Total current assets	47,474,589	36,281,544
Property, plant and equipment, net	16,811,639	15,960,731
Goodwill	25,209,336	25,209,336
Intangible assets, net	37,857,801	47,560,406
Other assets	1,271,381	1,263,375
Total assets	128,624,746	126,275,392
Current Liabilities
Accounts payable	2,266,337	5,661,173
Accrued liabilities	7,178,022	4,322,901
Long-term debt, current	1,361,148	1,109,612
Notes payable, current	882,696	816,776
Unearned revenues	4,643,033	4,334,120
Total current liabilities	16,331,236	16,244,582
Long-term Liabilities
Deferred income taxes	14,519,460	18,176,190
Notes payable	1,254,609	825,897
Long-term debt	13,638,852	13,890,388
Acquisition-related contingent consideration	13,460,000	18,260,000
Other long-term liabilities	3,467,248	804,546
Total liabilities	$ 62,671,405	$ 68,201,603
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 0.01 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2015 and December 31, 2014	$ 100	$ 100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 55,453,014 and 36,783,857 shares, at June 30, 2015 and December 31, 2014, respectively	55,453	36,784
Additional paid-in capital	394,589,826	350,428,903
Treasury stock, at cost	(705,742)	(705,742)
Accumulated deficit	(327,559,694)	(291,246,538)
Accumulated other comprehensive income	1,866	1,329
Total Caladrius Biosciences, Inc. stockholders' equity	66,381,809	58,514,836
Noncontrolling interests	(428,468)	(441,047)
Total equity	65,953,341	58,073,789
Liabilities and Equity, Total	$ 128,624,746	$ 126,275,392